News
18.09.2018 | Press Release
Neurimmune Achieves Milestone in Collaboration with Ono Pharmaceutical12.09.2018 | Company News
Neurimmune appoints Christoph Hock as Chief Medical Officer to lead clinical development04.05.2018 | Company News
Michael Salzmann honored as Corporate Professional of the Year by The M&A Advisor26.04.2018 | Company News
Neurimmune appoints Fabian Buller as Chief Business Officer09.11.2017 | Press Release
Neurimmune Announces Collaboration with Ono Pharmaceutical in Neurodegenerative Diseases Field24.10.2017 | Company News
Neurimmune Raises $150 Million to Finance its Growth Strategy19.02.2017 | Company News
BIIB076 Moves into Phase 1 for Alzheimer's Disease26.01.2017 | Company News
Neurimmune's joint research project with University of Zurich awarded Pfizer Research Prize 2017